HC 067047

Potent and selective TRPV4 antagonist CAS# 883031-03-6

HC 067047

2D Structure

Catalog No. BCC7861----Order now to get a substantial discount!

Product Name & Size Price Stock
HC 067047: 5mg $115 In Stock
HC 067047: 10mg Please Inquire In Stock
HC 067047: 20mg Please Inquire Please Inquire
HC 067047: 50mg Please Inquire Please Inquire
HC 067047: 100mg Please Inquire Please Inquire
HC 067047: 200mg Please Inquire Please Inquire
HC 067047: 500mg Please Inquire Please Inquire
HC 067047: 1000mg Please Inquire Please Inquire
Related Products
  • A 967079

    Catalog No.:BCC7967
    CAS No.:1170613-55-4
  • Icilin

    Catalog No.:BCC4074
    CAS No.:36945-98-9
  • CMX001

    Catalog No.:BCC4106
    CAS No.:444805-28-1
  • AP 18

    Catalog No.:BCC7634
    CAS No.:55224-94-7
  • A 784168

    Catalog No.:BCC6140
    CAS No.:824982-41-4
  • 6-Iodonordihydrocapsaicin

    Catalog No.:BCC5860
    CAS No.:859171-97-4

Quality Control of HC 067047

3D structure

Package In Stock

HC 067047

Number of papers citing our products

Chemical Properties of HC 067047

Cas No. 883031-03-6 SDF Download SDF
PubChem ID 2742550 Appearance Powder
Formula C26H28F3N3O2 M.Wt 471.51
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 50 mg/mL (106.04 mM; Need ultrasonic)
Chemical Name 2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-N-[3-(trifluoromethyl)phenyl]pyrrole-3-carboxamide
SMILES CC1=C(C=C(N1CCCN2CCOCC2)C3=CC=CC=C3)C(=O)NC4=CC=CC(=C4)C(F)(F)F
Standard InChIKey NCZYSQOTAYFTNM-UHFFFAOYSA-N
Standard InChI InChI=1S/C26H28F3N3O2/c1-19-23(25(33)30-22-10-5-9-21(17-22)26(27,28)29)18-24(20-7-3-2-4-8-20)32(19)12-6-11-31-13-15-34-16-14-31/h2-5,7-10,17-18H,6,11-16H2,1H3,(H,30,33)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of HC 067047

DescriptionPotent and selective TRPV4 antagonist. Reversibly inhibits currents through mouse, human and rat TRPV4 orthologs (IC50 values are 17, 48 and 133 nM respectively). Also inhibits the endogenous TRPV4-mediated response to 4α-PDH (IC50 = 22 nM). Selective for TRPV4 over TRPV1, TRPV2, TRPV3 and TRPM8 channels.

HC 067047 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

HC 067047 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of HC 067047

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1208 mL 10.6042 mL 21.2085 mL 42.4169 mL 53.0211 mL
5 mM 0.4242 mL 2.1208 mL 4.2417 mL 8.4834 mL 10.6042 mL
10 mM 0.2121 mL 1.0604 mL 2.1208 mL 4.2417 mL 5.3021 mL
50 mM 0.0424 mL 0.2121 mL 0.4242 mL 0.8483 mL 1.0604 mL
100 mM 0.0212 mL 0.106 mL 0.2121 mL 0.4242 mL 0.5302 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on HC 067047

HC-067047 is a potent and selective TRPV4 antagonist with IC50 values of 48 ± 6 nM, 133 ± 25 nM, and 17 ± 3 nM, respectively in human, rat, and mouse. Also inhibits the endogenous TRPV4-mediated response to 4α-PDH (IC50 = 22 nM). target: TRPV4 IC 50: 48 ± 6 nM (human), 133 ± 25 nM (rat) , and 17 ± 3 nM (mouse) 1) The reference for administration of HC-067047 is 10 mg/kg (i.P) 2) HC-067047 caused a significant reduction of the maximal micturition pressure in rats, which might be caused by an effect on TRPV4 in smooth muscle. 3) HC-067047 Reduces Pollakisuria and Increases Functional Bladder Capacity 4) HC-067047 exhibits high selectivity toward TRPV4: IC50 values were at least 100-fold higher for the closely related channels TRPV1, TRPV2, and TRPV3, and 10-fold higher for TRPM8 and hERG.

References:
[1]. Everaerts W et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis.Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084-9.

Featured Products
New Products
 

References on HC 067047

Carrier Decay Properties of Mixed Cation Formamidinium-Methylammonium Lead Iodide Perovskite [HC(NH2)2]1-x[CH3NH3]xPbI3 Nanorods.[Pubmed:27973912]

J Phys Chem Lett. 2016 Dec 15;7(24):5036-5043.

Organic-inorganic lead iodide perovskites are efficient materials for photovoltaics and light-emitting diodes. We report carrier decay dynamics of nanorods of mixed cation formamidinium and methylammonium lead iodide perovskites [HC(NH2)2]1-x[CH3NH3]xPbI3 (FA1-xMAxPbI3) synthesized through a simple solution method. The structure and FA/MA composition ratio of the single-crystal FA1-xMAxPbI3 nanorods are fully characterized, which shows that the mixed cation FA1-xMAxPbI3 nanorods are stabilized in the perovskite structure. The photoluminescence (PL) emission from FA1-xMAxPbI3 nanorods continuously shifts from 821 to 782 nm as the MA ratio (x) increases from 0 to 1 and is shown to be inhomogeneously broadened. Time-resolved PL from individual FA1-xMAxPbI3 nanorods demonstrates that lifetimes of mixed cation FA1-xMAxPbI3 nanorods are longer than those of the pure FAPbI3 or MAPbI3 nanorods, and the FA0.4MA0.6PbI3 displays the longest average PL lifetime of about 2 mus. These results suggest that mixed cation FA1-xMAxPbI3 perovskites are promising for high-efficiency photovoltaics and other optoelectronic applications.

Quantitative EEG (QEEG) Measures Differentiate Parkinson's Disease (PD) Patients from Healthy Controls (HC).[Pubmed:28167911]

Front Aging Neurosci. 2017 Jan 23;9:3.

Objectives: To find out which Quantitative EEG (QEEG) parameters could best distinguish patients with Parkinson's disease (PD) with and without Mild Cognitive Impairment from healthy individuals and to find an optimal method for feature selection. Background: Certain QEEG parameters have been seen to be associated with dementia in Parkinson's and Alzheimer's disease. Studies have also shown some parameters to be dependent on the stage of the disease. We wanted to investigate the differences in high-resolution QEEG measures between groups of PD patients and healthy individuals, and come up with a small subset of features that could accurately distinguish between the two groups. Methods: High-resolution 256-channel EEG were recorded in 50 PD patients (age 68.8 +/- 7.0 year; female/male 17/33) and 41 healthy controls (age 71.1 +/- 7.7 year; female/male 20/22). Data was processed to calculate the relative power in alpha, theta, delta, beta frequency bands across the different regions of the brain. Median, peak frequencies were also obtained and alpha1/theta ratios were calculated. Machine learning methods were applied to the data and compared. Additionally, penalized Logistic regression using LASSO was applied to the data in R and a subset of best-performing features was obtained. Results: Random Forest and LASSO were found to be optimal methods for feature selection. A group of six measures selected by LASSO was seen to have the most effect in differentiating healthy individuals from PD patients. The most important variables were the theta power in temporal left region and the alpha1/theta ratio in the central left region. Conclusion: The penalized regression method applied was helpful in selecting a small group of features from a dataset that had high multicollinearity.

Characterization and function analysis of a novel gene, Hc-maoc-1, in the parasitic nematode Haemonochus contortus.[Pubmed:28166831]

Parasit Vectors. 2017 Feb 6;10(1):67.

BACKGROUND: Enoyl-CoA hydratase (MAOC) is required for the biosynthesis of the fatty acid-derive side chains of the ascaroside via peroxisome beta-oxidation in the free-living nematode Caenorhabditis elegans. The derivative of dideoxy-sugar, ascarylose is used as dauer pheromones or daumones to induce development of the stress-resistant dauer larvae stage. METHODS: Hc-maoc-1 gene was obtained by searching the Wellcome Trusts Sanger Institute's H. contortus genomic database. qRT-PCR was performed to analyse the transcriptional levels of Hc-maoc-1 with different developmental stages as templates. IFA was carried out to determine the expression pattern in L3 larvae and micro-injection was used to verify the promoter activity of 5'-flanking region of Hc-maoc-1. Overexpression and RNAi experiments were applied in N2 strain to ascertain the gene function of Hc-maoc-1. RESULTS: The full-length cDNA of Hc-maoc-1 was 900 bp in length, which contained eight exons separated by seven introns and possessed the Hotdog domain and the MaoC-like domain, together with several other residues and a hydratase 2 motif. It was transcribed throughout the lifecycle and peaked in the fourth-stage larvae (L4) of H. contortus; however, its transcription level decreased in diapausing L4. The protein expression and location of Hc-MAOC-1 were mainly in the intestine of L3 larvae. Overexpression of Ce-maoc-1 and Hc-maoc-1 in C. elegans showed extended lifespan and increased body size. The protein Ce-MAOC-1 and Hc-MAOC-1 were localized in the intestine with a punctate pattern. In C. elegans, knockdown of Ce-maoc-1 conferred shortened lifespan and body lengths, decreased brood size and increased lipid storage. CONCLUSION: Caenorhabditis elegans was used as a model organism to ascertain the function of Hc-maoc-1 in H. contortus. Our results showed the similar characteristics and functions with Ce-maoc-1 and provided evidences of the potential functions of Hc-maoc-1 in biosynthesis of daumones in H. contortus.

Investigation on the structure-activity relationship of BaO promoting Pd/CeO2-ZrO2 catalysts for CO, HC and NOx conversions.[Pubmed:28262870]

Phys Chem Chem Phys. 2017 Mar 15;19(11):7844-7852.

Four different synthetic routes (co-precipitation, oxidation-precipitation, citric acid sol-gel and reversed microemulsion) are adopted to prepare barium modified Pd/CeO2-ZrO2 catalysts and their catalytic activity towards CO, HC and NOx conversions is studied. The surface and bulk properties of these catalysts are characterized via XRD, N2 adsorption, XPS, UV-Raman, H2-TPR, and in situ DRIFTS. The catalyst prepared via the co-precipitation method exhibits the optimum three-way catalytic behavior, which is mainly due to its superior redox ability, whereas the oxidation-precipitation synthesis renders the catalyst with the best homogeneity and thermal resistance. However, for the catalyst prepared via the sol-gel route, its worst NOx reduction capacity is verified by the scarce appearance of negatively charged Pd(0)-N[double bond, length as m-dash]O(delta-) species, which is related to the faster dissociation of NO based on in situ DRIFTS, and the abundance of surface CO-Pd(+) species reveals its unsatisfactory deep oxidizability of the HC reactant.

Description

HC-067047 is a potent and selective TRPV4 antagonist and reversibly inhibits currents through the human, rat, and mouse TRPV4 orthologs with IC50 values of 48 nM, 133 nM, and 17 nM, respectively.

Keywords:

HC 067047,883031-03-6,Natural Products,TRP Channel, buy HC 067047 , HC 067047 supplier , purchase HC 067047 , HC 067047 cost , HC 067047 manufacturer , order HC 067047 , high purity HC 067047

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: